Loading...
CDLX logo

Cardlytics, Inc.NasdaqGM:CDLX 주식 보고서

시가총액 US$33.0m
주가
US$5.20
US$1.08
383.7% 고평가 내재 할인율
1Y-70.9%
7D-23.2%
1D
포트폴리오 가치
보기

Cardlytics, Inc.

NasdaqGM:CDLX 주식 리포트

시가총액: US$33.0m

CDLX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Cardlytics, Inc. 경쟁사

가격 이력 및 성과

Cardlytics 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가US$5.20
52주 최고가US$32.80
52주 최저가US$4.70
베타0.58
1개월 변동-18.75%
3개월 변동-26.12%
1년 변동-70.95%
3년 변동-91.03%
5년 변동-99.52%
IPO 이후 변동-96.11%

최근 뉴스 및 업데이트

내러티브 업데이트 Jun 02

CDLX: Reset Expectations And Partner Exit Will Drive Future Repricing

Analysts have edged Cardlytics' fair value estimate up to about $1.08 per share, while tightening assumptions around discount rate, revenue contraction, profit margins and future P/E. This reflects recent price target cuts to $1 to $1.25 that they see as better aligned with updated guidance and the impact of the BofA exit and Bridg sale.
내러티브 업데이트 May 15

CDLX: Reset Guidance And Banking Shifts Will Drive Future Repricing Potential

Narrative update on Cardlytics The analyst price target for Cardlytics has shifted from $1.25 to $1.50, with analysts pointing to updated assumptions around discount rates, revenue trends, margins, and future P/E after recent resets in expectations following Q4 results, Q1 guidance, and the impact of the BofA exit and Bridg divestiture. Analyst Commentary Recent research has centered on how Cardlytics should be valued after its Q4 results, Q1 guidance, and the announced BofA exit and Bridg divestiture.
분석 기사 May 11

Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Cardlytics, Inc. ( NASDAQ:CDLX ) just released its latest first-quarter results and things are looking bullish...

Recent updates

내러티브 업데이트 Jun 02

CDLX: Reset Expectations And Partner Exit Will Drive Future Repricing

Analysts have edged Cardlytics' fair value estimate up to about $1.08 per share, while tightening assumptions around discount rate, revenue contraction, profit margins and future P/E. This reflects recent price target cuts to $1 to $1.25 that they see as better aligned with updated guidance and the impact of the BofA exit and Bridg sale.
내러티브 업데이트 May 15

CDLX: Reset Guidance And Banking Shifts Will Drive Future Repricing Potential

Narrative update on Cardlytics The analyst price target for Cardlytics has shifted from $1.25 to $1.50, with analysts pointing to updated assumptions around discount rates, revenue trends, margins, and future P/E after recent resets in expectations following Q4 results, Q1 guidance, and the impact of the BofA exit and Bridg divestiture. Analyst Commentary Recent research has centered on how Cardlytics should be valued after its Q4 results, Q1 guidance, and the announced BofA exit and Bridg divestiture.
분석 기사 May 11

Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Cardlytics, Inc. ( NASDAQ:CDLX ) just released its latest first-quarter results and things are looking bullish...
내러티브 업데이트 May 01

CDLX: Reset Expectations And Banking Partner Shifts Will Drive Future Repricing

Analysts have nudged Cardlytics' average price target lower to about $1, with cuts from $2 to $1 and from $1.50 to $1.25. These changes reflect updated views after Q4 results, Q1 guidance, and the expected impact of the BofA exit and Bridg divestiture.
내러티브 업데이트 Apr 17

CDLX: Reset Guidance And BofA Exit Will Drive Upside Potential

Narrative Update on Cardlytics Analysts have cut their Cardlytics price targets to a range of about $1 to $1.25, citing Q1 guidance that resets expectations following the Bank of America exit and Bridg divestiture and leaves the stock in what they describe as "show me" territory. Analyst Commentary Recent research updates underline that Q1 guidance and the effects of the Bank of America exit and Bridg divestiture are central to how analysts are framing Cardlytics today.
내러티브 업데이트 Apr 03

CDLX: Reset Expectations And Partner Changes Will Shape Future Repricing

Analysts have trimmed Cardlytics' implied fair value from about $1.29 to roughly $1.04. This reflects recent price target cuts to $1 and $1.25 as they factor in softer revenue expectations and the impact of the BofA exit and Bridg divestiture.
내러티브 업데이트 Mar 20

CDLX: Reset Guidance And One Bank Exit Will Define Upside Potential

Narrative update on Cardlytics Analysts have trimmed Cardlytics' implied fair value from about $2.00 to roughly $1.25, reflecting lower price targets around $1.00 to $1.25 after Q1 guidance reset expectations for revenue trends, margins and future P/E as the business adjusts to the BofA exit and Bridg divestiture. Analyst Commentary Recent Street research has centered on recalibrated price targets around Q1 guidance and the operational impact of the BofA exit and Bridg divestiture.
내러티브 업데이트 Mar 06

CDLX: Reset Expectations And CFO Return Will Support Future Rerating

Analysts have trimmed their Cardlytics price target from $1.50 to $1.25, reflecting updated assumptions around fair value, revenue trends, and profitability following recent guidance resets and business changes. Analyst Commentary Recent commentary around the reduced US$1.25 price target centers on how quickly Cardlytics can adjust to its updated outlook and business mix after the Q1 guidance reset, the BofA exit, and the Bridg divestiture.
분석 기사 Jan 08

Cardlytics, Inc. (NASDAQ:CDLX) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Those holding Cardlytics, Inc. ( NASDAQ:CDLX ) shares would be relieved that the share price has rebounded 30% in the...
Seeking Alpha Oct 06

Cardlytics: Debt Overhang Casts Shadow On Upside

Summary Cardlytics is dealing with a significant headwind in Q3 due to restrictions from its largest bank partner. CDLX sold off sharply following Q2 results, but has since rallied following a bullish report from Citron Research. Management is targeting positive FCF through growth with its newest large bank partner while also substantially lowering operating expenses. Debt remains the biggest risk, though the earliest maturity is not until April 2028. I remain cautious until I see evidence of sequential growth and improving cash burn. Read the full article on Seeking Alpha
내러티브 업데이트 Aug 08

Bank Partnerships And Data-Driven Marketing Will Shape Future Markets

The notable downward revision in Cardlytics’ price target reflects sharply reduced revenue growth forecasts and a higher discount rate, resulting in a new consensus fair value of $2.10. What's in the News Cardlytics provided Q3 2025 revenue guidance of $52.2 million to $58.2 million.
분석 기사 Jul 23

Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX) As Its Stock Soars 64%

Cardlytics, Inc. ( NASDAQ:CDLX ) shares have continued their recent momentum with a 64% gain in the last month alone...
분석 기사 Jul 05

Is Cardlytics (NASDAQ:CDLX) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 May 29

Cardlytics, Inc. (NASDAQ:CDLX) Soars 30% But It's A Story Of Risk Vs Reward

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...
분석 기사 Apr 07

Why Investors Shouldn't Be Surprised By Cardlytics, Inc.'s (NASDAQ:CDLX) 30% Share Price Plunge

Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 30% in the last thirty...
User avatar
새로운 내러티브 Apr 03

US Neobank And Taiwan Office Will Unlock New Markets

Expansion into new sectors and partnerships with financial institutions and neobanks is expected to diversify the customer base and boost revenue.
분석 기사 Mar 11

Cardlytics (NASDAQ:CDLX) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 Feb 21

Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX)

It's not a stretch to say that Cardlytics, Inc.'s ( NASDAQ:CDLX ) price-to-sales (or "P/S") ratio of 0.5x right now...
Seeking Alpha Feb 13

Cardlytics: Short-Term Headwinds Drive Long-Term Success

Summary Cardlytics, Inc. offers an asymmetric investment opportunity for those who can handle stock price volatility and slow business progress. Recent issues with ad deliveries have impacted revenue and market sentiment but positioned the company for long-term success. The shift to engagement-based pricing is expected to drive broader platform adoption. Trading at just 0.51x P/S and 1.10x EV/Revenue, Cardlytics presents significant upside potential from current valuations. Amex Partnership could add $600 million in market value based on $35 million in incremental EBITDA for 2025. Read the full article on Seeking Alpha
분석 기사 Jan 10

At US$3.35, Is It Time To Put Cardlytics, Inc. (NASDAQ:CDLX) On Your Watch List?

Cardlytics, Inc. ( NASDAQ:CDLX ), might not be a large cap stock, but it saw significant share price movement during...
Seeking Alpha Dec 07

Cardlytics Continues Revenue Contraction Amid Worsening Economics

Summary Cardlytics, Inc. beat revenue and earnings estimates, but faces declining unit economics and revenue stabilization challenges. The AdTech market is projected to grow significantly, yet CDLX struggles with delivery inefficiencies, declining ARPU, and advertiser hesitancy, impacting its financial performance. Recent financial trends show falling revenue, negative operating income, and high stock-based compensation, with significant cash burn and a 52.1% stock price decline over the past year. Management's turnaround efforts may take several quarters, with increased R&D spending expected to further negatively affect operating results. My outlook on CDLX is to sell. Read the full article on Seeking Alpha
분석 기사 Nov 23

Estimating The Intrinsic Value Of Cardlytics, Inc. (NASDAQ:CDLX)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Cardlytics fair value estimate is US$3.50 Current share price...
분석 기사 Nov 05

After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...
분석 기사 Oct 15

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha Sep 17

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Summary Shares have fallen nearly 50% since the Q2 earnings report, which came in well below management’s guidance. With Q3 guidance pointing to further weakness, the company’s financial health hinges on management’s execution towards solving the ongoing issues on its ads platform. Assuming no additional setbacks, the company should return to growth next year and generate positive FCF. While risks remain high, the current valuation is undemanding, leading me to maintain a Neutral rating. Read the full article on Seeking Alpha
분석 기사 Aug 09

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders that were waiting for something to happen have been dealt a blow with a...
Seeking Alpha Jul 02

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Summary Cardlytics shares have declined significantly after Q1 earnings came in below management’s guidance. Key metrics show that the business is performing well. Recent steps taken by management have extended its debt until 2029, leaving the company in a more stable financial position. CDLX has multiple growth levers and significant risks that investors should consider. Read the full article on Seeking Alpha
분석 기사 May 31

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

The Cardlytics, Inc. ( NASDAQ:CDLX ) share price has softened a substantial 30% over the previous 30 days, handing back...
Seeking Alpha Apr 17

The Power Of Cardlytics' Data Partnerships Including Bank of America

Summary Cardlytics recently appointed Liane Hornsey to its Board of Directors, which could attract new investors and accelerate hiring and productivity. The company offers a suite of solutions for advertising, marketing, and customer engagement through its own mobile application and partnerships with financial institutions. Future growth projects, synergies, database integration, and new partnerships have the potential to drive net sales growth and increase investor attention. Read the full article on Seeking Alpha
분석 기사 Apr 10

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Despite an already strong run, Cardlytics, Inc. ( NASDAQ:CDLX ) shares have been powering on, with a gain of 81% in the...
Seeking Alpha Feb 16

Cardlytics: Good Prospects But Macro Uncertain

Summary Cardlytics has access to 50% of card swipe data through its relationships with major US consumer banks. The company's acquisitions of Dosh and Bridg have strengthened and diversified its platform. The impact of macroeconomic factors on consumer spending and advertising budgets may constrain Cardlytics' growth in the short to medium term. Read the full article on Seeking Alpha
분석 기사 Jan 18

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 29% in the last thirty...
분석 기사 Jan 04

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

주주 수익률

CDLXUS MediaUS 시장
7D-23.2%-4.0%-2.5%
1Y-70.9%-15.7%22.7%

수익률 대 산업: CDLX은 지난 1년 동안 -15.7%의 수익을 기록한 US Media 산업보다 저조한 성과를 냈습니다.

수익률 대 시장: CDLX은 지난 1년 동안 22.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.

주가 변동성

Is CDLX's price volatile compared to industry and market?
CDLX volatility
CDLX Average Weekly Movement14.7%
Media Industry Average Movement8.4%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

안정적인 주가: CDLX의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.

시간에 따른 변동성: CDLX의 주간 변동성은 지난 1년간 22%에서 15%로 감소했지만 여전히 US 종목의 상위 75%보다 높습니다.

회사 소개

설립직원 수CEO웹사이트
2008275Amit Guptawww.cardlytics.com

는 미국과 영국에서 광고 플랫폼을 운영하고 있습니다. 이 회사는 마케터가 온라인, 모바일 애플리케이션, 이메일, 다양한 실시간 알림 등의 디지털 채널을 통해 고객에게 도달할 수 있도록 하는 독점적인 네이티브 은행 광고 채널인 Cardlytics 플랫폼과 제품별 구매 데이터를 포함한 판매자 데이터 파트너의 POS 데이터를 활용하여 마케터가 분석 및 타겟 로열티 마케팅을 수행하고 마케팅의 효과를 측정할 수 있도록 하는 고객 데이터 플랫폼인 Bridg 플랫폼을 제공합니다. 는 2008년에 설립되었으며 조지아주 애틀랜타에 본사를 두고 있습니다.

Cardlytics, Inc. 기초 지표 요약

Cardlytics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
CDLX 기초 통계
시가총액US$32.95m
순이익 (TTM)-US$106.97m
매출 (TTM)US$211.16m
0.1x
주가매출비율(P/S)
-0.3x
주가수익비율(P/E)

CDLX는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
CDLX 손익계산서 (TTM)
매출US$211.16m
매출원가US$110.95m
총이익US$100.21m
기타 비용US$207.18m
순이익-US$106.97m

최근 보고된 실적

Mar 31, 2026

다음 실적 발표일

해당 없음

주당순이익(EPS)-19.42
총이익률47.46%
순이익률-50.66%
부채/자본 비율-5,101.2%

CDLX의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/06/08 02:13
종가2026/06/08 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Cardlytics, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Omar DessoukyBofA Global Research
Jason KreyerCraig-Hallum Capital Group LLC
Robert CoolbrithEvercore ISI